News Release

**RIBOMIC Announces Termination of MTA with The Pritzker Neuropsychiatric Disorders Research Consortium**

TOKYO, May 13, 2021 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced that the Material Transfer Agreement with the University of Michigan, a member of The Pritzker Neuropsychiatric Disorders Research Consortium, has been terminated. Under the MTA, the effects of anti-FGF9 aptamer have been tested to assess possible applications to psychiatric disorders.

RIBOMIC plans to continue assessment of the anti FGF-9 aptamer in-house.

**ABOUT RIBOMIC**

RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, pain and many other conditions.
See RIBOMIC website for more information.
https://www.ribomic.com/eng/

**Forward-Looking Statements**

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.
Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:
RIBOMIC Inc.
Finance and Accounting
ir.inquiry@ribomic.com